Protocol Ledger

NCT04796623 · Phase II · COMPLETED

A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer

Interventional Phase II clinical trial protocol NCT04796623 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-02-04 Enrollment: 122 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04796623
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)122 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04796623
Protocol FieldVerified Registry Value
NCT IdentifierNCT04796623
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment122 participants (ACTUAL)
Registered Start Date2021-02-04
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT04796623
Hospital Research SiteLocationSite Profile
Chongqing University Cancer HospitalChongqing, ChinaOpen Hospital Dossier ->
Sun Yat-sen University Cancer CenterGuangzhou, ChinaOpen Hospital Dossier ->
The Fourth Hospital of Hebei Medical UniversityShijiazhuang, ChinaOpen Hospital Dossier ->
Hunan Cancer HospitalChangsha, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI